Business Description
Deutsche Biotech Innovativ AG
ISIN : DE000A0Z25L1
Description
Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The company develops Adrecizumab, a monoclonal adrenomedullin-specific antibody, which is in Phase II clinical trial as a therapy against septic shock to reduce sepsis mortality. It also develops various drugs for the prevention of breast cancer and tumor.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -0.26 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 48.9 | |||||
| 3-Year FCF Growth Rate | -31.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -51.75 | |||||
| 12-1 Month Momentum % | -78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.02 | |||||
| Quick Ratio | 0.02 | |||||
| Cash Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -808.89 | |||||
| ROA % | -58.09 | |||||
| ROIC % | -2.73 | |||||
| 3-Year ROIIC % | -58.23 | |||||
| ROC (Joel Greenblatt) % | -29085.71 | |||||
| ROCE % | -122.8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | N/A |
N/A
|
N/A
| |||
| PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
| EV-to-EBIT | -4.53 | |||||
| EV-to-EBITDA | -94.18 | |||||
| EV-to-FCF | -4.4 | |||||
| Earnings Yield (Greenblatt) % | -22.08 | |||||
| FCF Yield % | -22.69 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Deutsche Biotech Innovativ AG Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 71.68 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0.003571 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | -78 | ||
| 52-Week Range (€) | 5 - 50 | ||
| Shares Outstanding (Mil) | 0.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Deutsche Biotech Innovativ AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Deutsche Biotech Innovativ AG Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Deutsche Biotech Innovativ AG Frequently Asked Questions
What is Deutsche Biotech Innovativ AG(FRA:DBI)'s stock price today?
The current price of FRA:DBI is €5.05. The 52 week high of FRA:DBI is €50.00 and 52 week low is €5.00.
When is next earnings date of Deutsche Biotech Innovativ AG(FRA:DBI)?
The next earnings date of Deutsche Biotech Innovativ AG(FRA:DBI) is .
Does Deutsche Biotech Innovativ AG(FRA:DBI) pay dividends? If so, how much?
Deutsche Biotech Innovativ AG(FRA:DBI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers